Pharmaceutical Regulatory Affairs in Asia

This seminar will provide an overview of the key areas of pharmaceutical regulatory affairs in Asia including, China, Hong Kong SAR, Brunei, the Philippines, India, Indonesia, Malaysia, Singapore, Thailand, Cambodia, Laos, Vietnam, Taiwan, Korea, Japan

4-6 Apr 2018

GBP 1,849 1,549 *
EUR 2,589 2,169 *
USD 2,884 2,416 *
* When you book before 9 Feb

Book now

Course Overview


  • Gain an overview of the Asian Markets
  • Discuss outlines of company and product registration
  • Understand the Application Process
  • Assess the impact of recent regulatory developments in the region
  • Discuss harmonisation initiatives including ASEAN opportunities
  • Understand how Japan fits in the Asian regulatory landscape
  • Discover general country specific and regional requirements

Why you should attend

This seminar wil provide an overview of the key areas of pharmaceutical regulatory affairs in Asia, including India.

Who should attend

This seminar will be of particular interest to all those who need to learn about successful marketing authorisation applications and in-market regulatory compliance. You will find this seminar useful both as an introductory and/or refresher course.

Personnel from Analytical Research and Development, Clinical Development, Quality Assurance, new business development departments, regulatory authorities.

Meeting Timings


09.00 Registration and coffee
09.30 Meeting start
17.00 Meeting end


09.00 Meeting start
17.00 Meeting end


09.00 Meeting start
16.30 Meeting end


Day 1: China, Hong Kong SAR, Introduction to ASEAN, Brunei and the Philippines
Day 2: India, Indonesia, Malaysia, Singapore and Thailand, Cambodia, Laos, Vietnam
Day 3: Taiwan, Korea, brief comparison of Japan, ASEAN harmonisation

The Markets

  • Brief Commercial and Cultural Background
  • Importance of Major Markets

Company and Product Registration

  • Regulations and Guidelines
  • Drug Classification Systems
  • Site Registration
  • New Products
  • Line Extensions
  • Labelling Changes
  • Sourcing Changes
  • Registration Samples
  • Certificates / Legalisation

Application Process

  • Committees / Meetings
  • New Applications
  • Variations
  • Renewals / Re-registration

Recent Regulatory Developments

  • Influences and Changes: national and regional
  • The latest Regulatory Developments in the region

Harmonisation Initiatives

  • ASEAN Opportunities

A Brief comparison of how Japan fits into the Asian regulatory landscape

General Country-Specific and Regional Discussions


Monica Dressler-Meyer

Mónica Dressler-Meyer is DRA Manager based in Switzerland with several years of regulatory experience. She has spent many years in DRA working with different pharmaceutical companies with responsibility for Asia Pacific and lately also for development activities in other regions. Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years’ experience in industry basics and pre-clinical research. She has a Degree in Chemistry and Biochemistry from Basel University.

Alan Chalmers

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs. A graduate of Strathclyde University in Glasgow with a B.Sc. in Pharmacy with specialisation in Pharmaceutical Technology, his Ph.D. at Manchester University was in Pharmaceutical Formulation. From 1975-1978 he was Development Officer and Clinical Trials Pharmacist of Allen & Hanburys (part of the then Glaxo group). In 1978 he joined Ciba-Geigy in DRA. Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs.
He has been consultant to the IFPMA, WHO and other international bodies and was Chairman of the Organising Committee of the initial IFPMA Asian Regulatory Conferences in Hong Kong and Singapore and Rapporteur to the more recent conferences in China and Malaysia.
Since 1998 he has been an independent regulatory consultant and is Director of his own consultancy company Pharma International in Switzerland. He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy. More recently as accredited by Swissmedic, Dr. Chalmers is a Qualified Person supporting several Swiss pharmaceutical companies trading internationally with pharmaceuticals and medical devices.
He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech. Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Book now

4-6 Apr 2018
4-6 Apr 2018 Rembrandt Hotel, London GBP 1,849.00
EUR 2,589.00
USD 2,884.00
+ VAT @ 20.00%
GBP 1,549.00
EUR 2,169.00
USD 2,416.00
Until 9 Feb
Enrol now

Previous customers include...

  • Actavis Group PTC
  • Actelion Pharmaceutical Ltd
  • Altran Technologies
  • AstraZeneca AB
  • AstraZeneca UK Ltd
  • Biocompatibles UK Ltd
  • Business Monitor International Ltd
  • Centocor BV
  • CSL Behring AG
  • Ferring Pharmaceuticals A/S
  • Grunenthal GmbH
  • H. Lundbeck A/S
  • Helm AG
  • Kedrion SpA
  • Napp Pharmaceutical Group Ltd
  • Novo Nordisk A/S
  • Prostrakan Group Ltd
  • Reckitt Benckiser Healthcare (UK) Ltd
  • Sanofi Pasteur SA
  • Sanofi Synthelabo Recherche
  • Sanofi-Aventis
  • Sanofi-Aventis Recherche & Development
  • Smith & Nephew Wound Management
  • Solvay Deutschland GmbH
  • Takeda Development Centre Europe Ltd
  • Valeant Pharma Switzerland GmbH